An e-mail from PennyProfiles- Stock hunters pennyprofiles.listbot.com
Investors,
LAJD is searching for a second level of consolidation after it's recent peak above .60. The stock has risen well despite what appears to be a seller unloading his shares on the past several rises in the stock. It appears that the selling has is near completion. A normal retracement would be expected down to the .44 level but we could very well see a break above recent highs and settle above .60 before continuing on. Friday's PR leaves too many possibilities as to where a base is expected and rather then wait for a retracement we though that it would be prudent to position and wait for forthcoming developments.Judging by the recent PR's we could get new developments at anytime.The stock has done well holding it's ground and it also reacts well to volume. So far, it's relatively unknown and, IMO, is ripe for positioning. 20,000,000 shares outstanding. The float is unknown, however the stock trades as if the shares are extremely tightly held. We suspect they are and speculate the float to be in the neighborhood of 6-7 million shares. Please contribute to your own research in regards to LAJD.
Latest observations on LAJD
LAJD is the latest addition to our Bio-medical stocks that we intend to hold as long we see the distinct potential as presented through the latest waves of pr?s. LAJD provides an extensive range of products offering a range of OTC drugs and neutraceuticals nationally through a growing distributorship of over 1,000 clients. See a complete list of actively marketed products on their site:
Among the many products the company has to offer, two of them have caught our immediate attention. The re-introduction of a reformulated product, MigraSpray. MigraSpray has been on the market for the treatment of migraines with modest success and has been reformulated as to require no need for refrigeration or any other special handling. As a result the product, along with the pre-existing line of products has opened the doors to a number of new distributorships and can now be marketed on-line. MigraSpray is now much more marketable is poised to capture some of the $8 billion spent on headache medication every year.
What?s more interesting is and what I would define as huge potential is the fact that LAJD also supplies a range of diagnostic test to include the rapid response of everything from determining pregnancy to ( a more important marketing niche) the detection of a variety of specific tropical diseases prevalent in certain regions around the globe, primarily in third world countries no FDA intervention!. Our interest was peaked from the company?s development of a unique proprietary test for active Tuberculosis, which is expressed as having ?no equivalent in the market place?. TB has been again grown to epidemic proportions. There?s an incredibly huge market place for rapid testing of active Tuberculosis.
DEVELOPMENTS OF THE LAST WEEK:
To further secure the company?s potential, They have introduced three exceptional individuals to take on the duties of propelling LAJD as a fully emerging company.
PR: biz.yahoo.com
Shortly after the reconstruction of management Friday?s PR opened the door to some huge possibilities in regards to the company. READ THE PAST SEVERAL PR?s AS WELL !
Friday the company released the following PR: biz.yahoo.com
La Jolla Diagnostics Announces Ongoing Discussions Regarding DiagnosTech Subsidiary
Several companies have indicated an interest in the DiagnosTech, Inc. line of rapid diagnostic tests, especially the company's rapid test for active tuberculosis. Under discussion is the possibility of a strategic joint venture, license, merger or outright acquisition of DiagnosTech Inc.
The company cannot say what, if any, actions will be forthcoming as a result of these discussions. La Jolla Diagnostics is an emerging company engaged in the development and marketing of health care products, dietary supplements, and through its subsidiary DiagnosTech Inc., state-of-the-art rapid diagnostic tests including a unique proprietary test for active tuberculosis.
LAJD?s TB test is an addition to an existing line of diagnostic test available through its subsidiary, DiagnosTech Inc., which also include:
HIV I and II (AIDS) infection using serum/plasma HIV I and II (AIDS) infection using whole blood H. pylori infection (the causative agent in over 90% of ulcers) Hepatitis B (HBsAg) Pregnancy Trypanasoa cruzi infection (Chagas disease: a common parasitic infection) Toxoplasma gondii infection (a common infection among AIDS patients).
La Jolla Diagnostics Inc.
Don Brucker, 800/454-6790, Fax 619/454-7851
lajd.com
lajd96@aol.com
We are LONG LAJD as a speculative mid-long term position play as it's apparent to us that a tremendous amount of potential exist. Please do your own research as well.
Good trading,
Mic@PennyProfiles pennyprofiles.com
DISCLAIMER:
Penny Profiles makes no recommendations and encourages everyone to do their own due diligence!! We are not responsible for the results of your trading decisions. Nothing in this email shall constitute a solicitation or an offer to buy or sell any securities here in. All statements made are our own express opinion and should be treated as such. Everything contained in said email is for entertainment purposes only. There is never any need to merely rush into any stock ever mentioned through our e-mails.Penny Profiles is not compensated by any of the companies we mention. Trading in OTC stocks can be very risky and you can lose all or part of your money. All investment decisions should be discussed with a qualified investment professional.We are not liable for any losses or damages, monetary or otherwise, resulting from the use of our services. Penny Profiles does not received any compensation from any company we mention and are not a Broker/Dealer or Investment Advisor as licensed or registered by the NASD. Penny Profiles may or may not hold a position in any issue at any given time, but has no business or financial relationship with any of the companies mentioned herein, except in conducting normal DD and research.
"Internet Fraud" is available on the SEC's Web site, at
sec.gov.
PLEASE EXERCISE CAUTION
We honor all removals by simply responding to this e-mail and
typing "remove" in the subject line. |
